Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 14, 2021; 27(30): 5088-5099
Published online Aug 14, 2021. doi: 10.3748/wjg.v27.i30.5088
Published online Aug 14, 2021. doi: 10.3748/wjg.v27.i30.5088
Table 2 Child-Pugh constituent ratio
| Baseline | 1 mo | 3 mo | 6 mo | 12 mo | 24 mo | |
| TAF, n (%) | 9/18/5 (32) | 4/23/5 (32) | 3/23/6 (32) | 6/22/4 (32) | 7/18/2 (27) | 14/8/1 (23) |
| Child-Pugh A/B/C (%) | 28.1/56.3/15.6 | 12.5/71.9/12.7 | 12.7/74.6/15.6 | 18.8/68.8/12.5 | 25.9/66.7/7.4 | 60.9/34.8/4.3 |
| TDF(n) | 14/17/4 (35) | 4/25/6 (35) | 4/23/8 (35) | 7/21/5 (33) | 6/20/3 (29) | 7/11/3 (21) |
| Child-Pugh A/B/C (%) | 40.0/48.6/11.4 | 11.4/71.4/12.0 | 11.4/65.8/22.8 | 21.2/63.6/15.2 | 20.7/68.9/10.4 | 33.3/52.4/14.3 |
| ETV, n (%) | 21/37/12 (70) | 9/47/13 (69) | 6/47/16 (69) | 11/44/11 (66) | 11/42/6 (59) | 11/24/5 (40) |
| Child-Pugh A/B/C (%) | 30.3/52.9/17.1 | 13.1/68.1/18.8 | 8.7/68.1/23.2 | 16.7/66.6/16.7 | 18.6/71.2/10.2 | 27.5/60.0/12.5 |
- Citation: Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099
- URL: https://www.wjgnet.com/1007-9327/full/v27/i30/5088.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i30.5088